Helping women make sound decisions regarding discontinuation of systemic menopausal hormone therapy (MHT) represents a challenge for clinicians. The goal of striving for the lowest dose of MHT for the shortest amount of time would seem disconnected from the reality that many women experience vasomotor symptoms (VMS) for a decade or more [
- Kaunitz A.M.
Extended duration use of menopausal hormone therapy.
Menopause. 2014; 21: 679-681
2]. Thus, determining why, when and how to discontinue the use of MHT represent important clinical considerations.
- Kaunitz A.M.
- Manson J.E.
Management of menopausal symptoms.
Obstet. Gynecol. 2015; 126: 859-876
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Extended duration use of menopausal hormone therapy.Menopause. 2014; 21: 679-681
- Management of menopausal symptoms.Obstet. Gynecol. 2015; 126: 859-876
- Practice bulletin No. 141: management of menopausal symptoms.Obstet. Gynecol. 2014; 123: 202-216
- NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older.Menopause. 2015; 22: 685-686
- The 2012 hormone therapy position statement of The North American Menopause Society.Menopause. 2012; 19: 257-271
Published online: March 24, 2016
Accepted: March 22, 2016
Received: March 15, 2016
© 2016 Elsevier Ireland Ltd. All rights reserved.